^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    Treatment of Gastric Cancer Carcinomatosis. (PubMed, Surg Clin North Am)
    If patients with synchronous GCPM have stable disease following neoadjuvant therapy, surgical intervention can be considered. Patients with positive cytology or low-volume peritoneal disease (peritoneal carcinomatosis index &lsqb;PCI] < 7) may "convert" to negative cytology or resolution of peritoneal metastases following intraperitoneal therapy and may be candidates for subsequent gastrectomy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression
    2d
    Krukenberg tumours: which patients should be considered for surgery?-a narrative literature review. (PubMed, Transl Cancer Res)
    Diagnostic laparoscopy could be considered before debulking surgery, to assess resectability of disease and to avoid a futile exploratory laparotomy. HIPEC after cytoreductive surgery (CRS) remains controversial, with possible survival benefit for KTs of gastric origin, particularly when peritoneal dissemination is present but the PCI is low.
    Review • Journal • Surgery
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER expression
    3d
    Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions. (PubMed, BJC Rep)
    Our findings demonstrate the utility of the interactome in uncovering biological associations and in generating clinically translatable results.
    Journal
    |
    IL6 (Interleukin 6)
    3d
    The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study. (PubMed, Cancers (Basel))
    These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.
    Journal • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    3d
    PERCEPTION: Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, North Eastern German Society of Gynaecological Oncology | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin
    3d
    Nivolumab with or Without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=26, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    N-Plus: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (clinicaltrials.gov)
    P2, N=640, Recruiting, North Eastern German Society of Gynaecological Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    carboplatin • Zejula (niraparib)
    3d
    MAMOC: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (clinicaltrials.gov)
    P3, N=42, Completed, North Eastern German Society of Gynaecological Oncology | Active, not recruiting --> Completed | N=190 --> 42 | Trial completion date: Jan 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date
    |
    Avastin (bevacizumab) • carboplatin • Rubraca (rucaparib)
    3d
    Case report: The first known case of male retroperitoneal mesonephric-like adenocarcinoma. (PubMed, Front Oncol)
    MLA in the retroperitoneum of men has not been reported yet. The diverse morphology and unclear molecular characteristics of this tumor mandate careful diagnosis for good clinical outcomes.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • AR (Androgen receptor) • WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin) • MME (Membrane Metalloendopeptidase) • ANO1 (Anoctamin 1) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
    |
    TP53 wild-type
    5d
    Comparison of Ovarian Tumor Homologous Recombination Deficiency (HRD) Status Generated from the Illumina TruSight Oncology 500 (TSO500) High-Throughput HRD Assay to the Myriad myChoice CDx Assay (AMP 2024)
    The FDA (US Food and Drug Administration) has approved olaparib as a front-line maintenance therapy in combination with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer with HRD+ status. We have demonstrated that the TSO500-HRD assay can accurately determine HRD status in ovarian tumors.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Myriad myChoice® CDx • TruSight Oncology 500 Assay • TruSight Oncology 500 HRD Assay
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    6d
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    8d
    Open versus laparoscopic resection of retroperitoneal tumors involving major vessels: a propensity score–matched study (ChiCTR2400090383)
    P=N/A, N=327, Recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    8d
    Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial (ChiCTR2400090496)
    P2, N=132, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • paclitaxel • Yidafan (ivonescimab)
    10d
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Washington | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    UW-Oncoplex™
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    11d
    STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=58, Recruiting, Sutro Biopharma, Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • luveltamab tazevibulin (STRO-002)
    11d
    3D-PEDSURG: Contribution of 3D Modeling in Surgical Management of Pediatric Retroperitoneal and Pelvic Tumors (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Sep 2026 | Initiation date: Jun 2024 --> Sep 2024 | Trial primary completion date: May 2026 --> Aug 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    12d
    In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis. (PubMed, J Immunother Cancer)
    The combination of in situ PDT locally delivered by an endoscope light and iDC administration induces a durable memory immune response against peritoneal carcinomatosis thereby opening new perspectives for the treatment of a life-threatening condition.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    RSL3
    13d
    LYL797-101: A Study to Investigate LYL797 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    LYL797
    13d
    Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery. (PubMed, Int J Gynecol Cancer)
    The study supports the critical need for timely risk-reducing surgery in high-risk populations, as well as a comprehensive pathologic examination along with vigilant post-operative surveillance. Consensus guidelines for management of serous tubal intraepithelial carcinoma are necessary to identify a group of patients at higher risk of progression to primary peritoneal carcinoma and optimize patient care.
    Journal • Surgery
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    14d
    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Pfizer | Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Zirabev (bevacizumab-bvzr)
    14d
    EFFORT: Adavosertib with or Without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)
    15d
    Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis. (PubMed, Cancer Immunol Immunother)
    Furthermore, MSLN-CAR.CIK penetrated the inner levels of OC spheroids exerting effective tumor killing. Our findings provide currently unknown therapeutically relevant information on intraperitoneal approaches with CAR.CIK, supporting further developments and improvements for clinical studies in the context of locoregional cell therapy approaches for patients with PC from OC.
    Journal
    |
    MSLN (Mesothelin)
    17d
    Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy. (PubMed, Cancer Biol Med)
    NK cell immunotherapy inhibited proliferation of MPM cells in vitro and in vivo with a good safety profile.
    Preclinical • Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
    17d
    Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis. (PubMed, Biochem Biophys Res Commun)
    In conclusion, the triple-regulated Surv.m-CRA-CEAp enhances cancer specificity (i.e., safety) without reducing the potent therapeutic effect for carcinoembryonic antigen-positive gastric cancer-derived peritoneal carcinomatosis. The modified E1B promoter strategy of CRA facilitates the development of novel CRAs for the effective and safe treatment of a variety of refractory cancers.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression • CEACAM5 positive
    18d
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Pfizer | Phase classification: P1/2 --> P2
    Phase classification • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    18d
    Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (clinicaltrials.gov)
    P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial primary completion date: Jun 2025 --> Jan 2026
    Trial primary completion date • Patient reported outcomes
    19d
    Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Sichuan University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    19d
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)
    19d
    Preventive intervention with Agaricus blazei murill polysaccharide exerts anti-tumor immune effect on intraperitoneal metastasis colorectal cancer. (PubMed, Int J Biol Macromol)
    In addition, preventive intervention with ABMP increased ω-3 polyunsaturated fatty acids content in intraperitoneal TME, revealing that ABMP shifted the metabolic landscape of the TME to promote T cell function and achieved immune regulation. These results suggest that the inhibitory effect of ABMP on colon cancer may be tumor stage-dependent, and that remodeling of fatty acid composition may be an important determinant of its action at any given stage.
    Journal
    |
    CD8 (cluster of differentiation 8)
    20d
    Case report: HPV related pelvic retroperitoneal squamous cell cancer of unknown primary presenting as ovary neoplasm. (PubMed, Int J Surg Case Rep)
    HPV infection may contribute to the development of PRSCC. Complete surgical resection, with adjuvant radiotherapy and chemotherapy, is a viable treatment approach.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MUC16 (Mucin 16, Cell Surface Associated)
    20d
    The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer. (PubMed, Sci Rep)
    In the case of the strong implication of BRCA PV/LPV with a negative result with one genetic test, different platforms could be considered in limited cases. Careful interpretation and further studies for the cross-validation of gene analysis platforms are needed.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    21d
    AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Oct 2024
    Trial completion • Trial completion date
    |
    Imfinzi (durvalumab) • batiraxcept (AVB-500)
    21d
    DWI-HighRisk: Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Laval University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • MRI
    21d
    DWI-PDAC: Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. (clinicaltrials.gov)
    P=N/A, N=40, Active, not recruiting, Laval University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • MRI
    24d
    Nodular Histiocytic Aggregates of the Greater Omentum Mimicking Peritoneal Carcinomatosis on Imaging. (PubMed, Cureus)
    In our case report, NHMH presents with diffuse infiltration of the greater omentum on imaging. This emphasizes the importance of recognizing this pathological entity along with clinicopathological correlation to avoid misdiagnosis that may adversely affect patient outcomes.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    25d
    HIPEC for Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=51, Completed, Albert Einstein College of Medicine | Trial completion date: Nov 2020 --> Aug 2024
    Trial completion date
    |
    mitomycin
    25d
    NRG-GY007: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=147, Active, not recruiting, NRG Oncology | Trial completion date: Sep 2022 --> Aug 2025
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CRP (C-reactive protein)
    |
    carboplatin • paclitaxel • Jakafi (ruxolitinib)
    25d
    PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • gotistobart (BNT316)
    27d
    Desmoplastic Small Round Cell Tumor in a Young Adult: A Case Report Highlighting Diagnostic Challenges and Treatment Approaches. (PubMed, Cureus)
    The patient was placed on a regimen alternating the combination of vincristine, doxorubicin, and cyclophosphamide for one week and ifosfamide and etoposide for the next. It also discusses the complexity and challenges of managing this rare aggressive malignancy. This case report also addresses the necessity for advanced research into targeted therapies and optimized strategies in the treatment to help improve the survival rates and quality of life for patients with DSRCT.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    NCAM1 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine
    27d
    Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis. (PubMed, World J Surg Oncol)
    Our retrospective study demonstrates that PARP inhibitor maintenance therapy, including olaparib and niraparib, significantly prolongs PFS in patients with PSR epithelial ovarian, tubal, or primary peritoneal cancer, These findings support the broad utilization of PARP inhibitors as a standard maintenance therapy for PSR epithelial ovarian cancer irrespective of BRCA mutation status.
    Retrospective data • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib)
    28d
    MIROVA: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=136, Active, not recruiting, AGO Research GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FOLR1 ( Folate receptor alpha ) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)
    28d
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Recruiting, University of Washington | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • carboplatin